ALX Oncology Holdings (ALXO)
(Delayed Data from NSDQ)
$16.94 USD
-0.08 (-0.47%)
Updated May 1, 2024 04:00 PM ET
After-Market: $16.92 -0.02 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
ALX Oncology Holdings Inc. [ALXO]
Reports for Purchase
Showing records 1 - 20 ( 27 total )
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Catalyst-Rich 2024; New $20 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for ALXO 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Evorpacept Shines in Gastric Cancers; New PT $17.50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
MDS and AML Programs Shelved; Lower PT to $16; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Focus Remains on ASPEN-02 and ASPEN-06 Updates in 2H23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Eyes on Upcoming MDS Data From ASPEN-02 Study; PT Lowered To $30; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways From Our Fireside Chat with Dr. Michael Bishop on AML
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
ASPEN-05 Data Update Highlights Evorpacepts Potential in Newly Diagnosed AML; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Promising Phase 1 Data of ASPEN-05 at ASH; Adusting PT to $65; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Expanding Solid Tumor Indications; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Key MDS Readout in 2022; Lower PT to $80; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Evorpacept has potential in MDS; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Does Smoke from CD47 Program at SITC Signal Further Flames at ASH?
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
Sell-off on ASPEN-01 Update Offers Entry Opportunity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: ALX Oncology Holdings Inc.
Industry: Medical - Biomedical and Genetics
SHIELD Platform Could Help Deepen Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S